OVID
Ovid Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.80
+0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6M | 7.3M | 566.0K | 392.0K | 1.5M |
| Cost of Revenue | — | 300.0K | — | — | — |
| Gross Profit | 1.6M | 7.0M | 566.0K | 392.0K | 1.5M |
| Operating Expenses | |||||
| R&D Expense | 33.6M | 25.6M | 36.8M | 28.6M | 24.6M |
| SG&A Expense | 26.0M | 24.1M | 25.7M | 29.6M | 32.4M |
| General & Admin Expense | 26.0M | 24.1M | 25.7M | 29.6M | 32.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 300.0K | (300.0K) | 1.0K | 1.5M | 510.00 |
| Total Operating Expenses | 59.9M | 49.4M | 62.5M | 59.7M | 57.1M |
| Cost and Expenses | 59.9M | 49.7M | 62.5M | 59.7M | 57.1M |
| Operating Income (EBIT) | (58.4M) | (42.4M) | (61.9M) | (59.3M) | (55.5M) |
| Non-Operating | |||||
| Interest Income | — | — | 3.9M | 4.9M | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | 3.9M | 4.9M | — |
| Other Non-Op Income/Expense | 23.9M | 25.0M | 35.5M | 6.9M | 1.4M |
| Non-Operating Income (excl Interest) | (22.6M) | (25.0M) | (3.5M) | (1.7M) | (510.00) |
| EBT (Pre-Tax Income) | (34.5M) | (17.4M) | (26.4M) | (52.3M) | (54.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (34.5M) | (17.4M) | (26.4M) | (52.3M) | (54.2M) |
| Earnings from Cont. Ops | (34.5M) | (17.4M) | (26.4M) | (52.3M) | (54.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.5M) | (17.4M) | (26.4M) | (51.4M) | (54.2M) |
| Per Share | |||||
| Basic EPS | ($0.48) | ($0.24) | ($0.37) | ($0.74) | ($0.77) |
| Diluted EPS | ($0.48) | ($0.24) | ($0.37) | ($0.74) | ($0.77) |
| Revenue Per Share | $0.02 | $0.10 | $0.01 | $0.01 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 73.7M | 73.7M | 70.9M | 70.6M | 70.4M |
| Diluted Shares Outstanding | 73.7M | 73.7M | 70.9M | 70.6M | 70.4M |
| Profitability Metrics | |||||
| EBITDA | (35.7M) | (17.1M) | (57.8M) | (57.0M) | (54.2M) |
| D&A | 84.0K | 300.0K | 613.0K | 568.0K | 1.4M |
| EBIT | (35.7M) | (17.4M) | (58.4M) | (57.6M) | (55.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026